Calidi Biotherapeutics CLDI
NYSE CLDI
$1.06 -0.01 (-0.93%)
As of: Oct 1, 2026 · 12:58 PM EDT

Calidi Biotherapeutics (CLDI) Convertible Debt (2024)

Updated

Calidi Biotherapeutics (CLDI) reported Convertible Debt of $1.77 million for Q3 2024, down 7.9% from the prior quarter.

Analysis

Calidi Biotherapeutics (CLDI) Convertible Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Calidi Biotherapeutics 1.50 Mn -23.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 1.77 Mn
Jun 30, 2024 1.93 Mn
Mar 31, 2024 3.38 Mn
API Access

Calidi Biotherapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=CLDI&period=max&api_key=YOUR_API_KEY